December 06, 2024

Joint research in key technologies: NMI and KIT sign cooperation agreement

Joint research in key technologies: NMI and KIT sign cooperation agreement

The NMI Natural and Medical Sciences Institute and the Karlsruhe Institute of Technology (KIT) have signed a groundbreaking cooperation agreement. This partnership combines the expertise of both institutions in the fields of production and characterization of materials for biological systems and energy storage as well as the application of statistical methods in medicine.

The collaboration will focus on several future-oriented fields of research, such as joint research on different forms of analytics, 3D bioprinting, environmentally friendly energy storage, measures against respiratory infections and AI-supported diagnosis of proteins. The NMI and KIT have already successfully carried out joint research projects in the past. This demonstrates their long-standing collaboration in the fields of biotechnology, medicine and materials science.

“We are excited about the many synergies that will result from the collaboration with KIT and look forward to jointly developing innovative solutions that will be of great benefit to both industry and society,” explains Prof. Dr. Katja Schenke-Layland, Director of the NMI.

“With the cooperation agreement, KIT and the NMI are intensifying their long-standing and trusting collaboration in the fields of biotechnology, medicine and materials science. The resulting innovations will strengthen the locations Baden-Württemberg and Germany,” says Prof. Dr. Thomas Hirth, Vice President International and Transfer at KIT.

As a research university in the Helmholtz Association, KIT is one of Germany’s leading scientific institutions in the engineering and natural sciences. With its interdisciplinary research and close collaboration with partners from industry, it offers an excellent basis for innovative cooperation. In particular, the clusters of excellence and the Helmholtz Institute Ulm for Electrochemical Energy Storage founded by KIT open up promising prospects for the further development of new technologies in partnership. The aim of the cooperation between the NMI and KIT is to work on significant scientific and technological advances that will benefit both sides.

About the KIT:

The Karlsruhe Institute of Technology is one of the most renowned technical universities in Germany. It combines strong basic research with application-oriented development in engineering and natural sciences. Thanks to its interdisciplinary orientation and close links with industry, KIT is a pioneer in the development of future-oriented technologies.

https://www.kit.edu/index.php

Our latest News

discover more
Why pain persists long after injuries have healed

Why pain persists long after injuries have healed

Prof. Dr. Rohini Kuner of the Heidelberg Faculty of Medicine at Heidelberg University awarded the 2026 Jung Prize for Medicine Chronic pain is among the most common and burdensome health conditions worldwide. But which processes in the nervous system cause pain to be “learned” and thus persist long term? And how can insights into the […]

New HI-STEM Publication: A kinetics-based model of haematopoiesisreveals extrinsic regulation of skewed lineageoutput from stem cells

New HI-STEM Publication: A kinetics-based model of haematopoiesisreveals extrinsic regulation of skewed lineageoutput from stem cells

Rodríguez-Correa, E., Grünschläger, F., Nizharadze, T. et al. A kinetics-based model of haematopoiesis reveals extrinsic regulation of skewed lineage output from stem cells. Nat Cell Biol (2026). https://doi.org/10.1038/s41556-026-01958-0 https://www.nature.com/articles/s41556-026-01958-0 Abstract Haematopoietic stem cells (HSCs) display extensive molecular and functional heterogeneity. However, a cohesive model that explains the relationship and biological relevance of these diverse HSC states remains elusive. Here, […]

Heidelberg-based development revolutionizes hepatitis D therapy worldwide: US Food and Drug Administration (FDA) approves hepatitis drug Hepcludex (bulevirtide)

Heidelberg-based development revolutionizes hepatitis D therapy worldwide: US Food and Drug Administration (FDA) approves hepatitis drug Hepcludex (bulevirtide)

Joint press release of the Heidelberg Faculty of Medicine at Heidelberg University and the German Center for Infection Research: With the FDA approval of Hepcludex (bulevirtide), a therapy for chronic hepatitis D developed at the Heidelberg Faculty of Medicine at Heidelberg University, Heidelberg University Hospital, and the German Center for Infection Research (DZIF) has now […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp